CA3132987A1 - Rad51 inhibitors - Google Patents
Rad51 inhibitors Download PDFInfo
- Publication number
- CA3132987A1 CA3132987A1 CA3132987A CA3132987A CA3132987A1 CA 3132987 A1 CA3132987 A1 CA 3132987A1 CA 3132987 A CA3132987 A CA 3132987A CA 3132987 A CA3132987 A CA 3132987A CA 3132987 A1 CA3132987 A1 CA 3132987A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- optionally substituted
- alkyl
- butyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816998P | 2019-03-12 | 2019-03-12 | |
| US62/816,998 | 2019-03-12 | ||
| PCT/US2020/022293 WO2020186006A1 (en) | 2019-03-12 | 2020-03-12 | Rad51 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3132987A1 true CA3132987A1 (en) | 2020-09-17 |
Family
ID=72422797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3132987A Pending CA3132987A1 (en) | 2019-03-12 | 2020-03-12 | Rad51 inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11247988B2 (https=) |
| EP (1) | EP3938358B1 (https=) |
| JP (1) | JP7460649B2 (https=) |
| KR (1) | KR20210127790A (https=) |
| CN (1) | CN114072390B (https=) |
| AU (1) | AU2020235089A1 (https=) |
| BR (1) | BR112021017336A2 (https=) |
| CA (1) | CA3132987A1 (https=) |
| IL (1) | IL285889B2 (https=) |
| MX (1) | MX2021010916A (https=) |
| PH (1) | PH12021552147A1 (https=) |
| SG (1) | SG11202109399SA (https=) |
| TW (1) | TW202104198A (https=) |
| WO (1) | WO2020186006A1 (https=) |
| ZA (1) | ZA202106284B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111263756B (zh) | 2017-07-11 | 2023-05-16 | 赛泰尔治疗公司 | Rad51抑制剂 |
| SG10202107087YA (en) | 2017-09-11 | 2021-07-29 | Cyteir Therapeutics Inc | Rad51 inhibitors |
| PH12021552147A1 (en) | 2019-03-12 | 2023-01-04 | Cyteir Therapeutics Inc | Rad51 inhibitors |
| PH12021552205A1 (en) | 2019-03-25 | 2022-06-13 | Cyteir Therapeutics Inc | Combinations of rad51 and parp inhibitors |
| KR20220024857A (ko) | 2019-06-21 | 2022-03-03 | 사이티어 테라퓨틱스, 인크. | 췌장암의 치료를 위한 rad51 억제제의 사용 방법 |
| WO2021164746A1 (zh) * | 2020-02-19 | 2021-08-26 | 江苏先声药业有限公司 | 取代芳基类化合物 |
| WO2023078271A1 (zh) * | 2021-11-02 | 2023-05-11 | 上海旭成医药科技有限公司 | 芳香化合物、其制备方法、中间体、药物组合物和应用 |
| WO2023185831A1 (zh) * | 2022-03-29 | 2023-10-05 | 正大天晴药业集团股份有限公司 | 含有噻唑环的化合物 |
| CN114736173B (zh) * | 2022-05-24 | 2024-06-11 | 无锡捷化医药科技有限公司 | 一种3-（二氟甲基）氧杂环丁烷-3-胺盐酸盐的制备方法 |
| EP4574817A1 (en) * | 2023-12-21 | 2025-06-25 | LoQus23 Therapeutics Limited | Inhibitory compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS6230780A (ja) | 1985-04-17 | 1987-02-09 | Ss Pharmaceut Co Ltd | １，７−ナフチリジン誘導体及びこれを含有する薬剤 |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| DE69132905T2 (de) | 1990-12-06 | 2002-08-01 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Detektion von Nukleinsäuresequenzen |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| WO2012113774A1 (en) | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| CN107007597A (zh) | 2012-05-31 | 2017-08-04 | 菲尼克斯药品股份公司 | 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物的制药用途 |
| JP2017100949A (ja) | 2014-04-01 | 2017-06-08 | 大日本住友製薬株式会社 | ５員環ヘテロアリール誘導体 |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| WO2016140971A1 (en) * | 2015-03-02 | 2016-09-09 | The Regents Of The University Of California | Novel rad51 inhibitors and uses thereof |
| US10442817B2 (en) * | 2015-06-04 | 2019-10-15 | Drexel University | Inhibitors of RAD52 recombination protein and methods using same |
| CN111263756B (zh) | 2017-07-11 | 2023-05-16 | 赛泰尔治疗公司 | Rad51抑制剂 |
| SG10202107087YA (en) | 2017-09-11 | 2021-07-29 | Cyteir Therapeutics Inc | Rad51 inhibitors |
| PH12021552147A1 (en) | 2019-03-12 | 2023-01-04 | Cyteir Therapeutics Inc | Rad51 inhibitors |
| PH12021552205A1 (en) | 2019-03-25 | 2022-06-13 | Cyteir Therapeutics Inc | Combinations of rad51 and parp inhibitors |
-
2020
- 2020-03-12 PH PH1/2021/552147A patent/PH12021552147A1/en unknown
- 2020-03-12 JP JP2021553834A patent/JP7460649B2/ja active Active
- 2020-03-12 IL IL285889A patent/IL285889B2/en unknown
- 2020-03-12 AU AU2020235089A patent/AU2020235089A1/en not_active Abandoned
- 2020-03-12 BR BR112021017336A patent/BR112021017336A2/pt not_active Application Discontinuation
- 2020-03-12 CA CA3132987A patent/CA3132987A1/en active Pending
- 2020-03-12 MX MX2021010916A patent/MX2021010916A/es unknown
- 2020-03-12 WO PCT/US2020/022293 patent/WO2020186006A1/en not_active Ceased
- 2020-03-12 US US16/816,393 patent/US11247988B2/en active Active
- 2020-03-12 CN CN202080035279.0A patent/CN114072390B/zh active Active
- 2020-03-12 TW TW109108203A patent/TW202104198A/zh unknown
- 2020-03-12 KR KR1020217032591A patent/KR20210127790A/ko not_active Abandoned
- 2020-03-12 SG SG11202109399SA patent/SG11202109399SA/en unknown
- 2020-03-12 EP EP20768883.9A patent/EP3938358B1/en active Active
-
2021
- 2021-08-30 ZA ZA2021/06284A patent/ZA202106284B/en unknown
- 2021-12-16 US US17/552,577 patent/US11932636B2/en active Active
-
2024
- 2024-01-30 US US18/427,164 patent/US20240360120A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021017336A2 (pt) | 2021-11-09 |
| JP2022525069A (ja) | 2022-05-11 |
| IL285889B2 (en) | 2024-09-01 |
| EP3938358A4 (en) | 2022-12-21 |
| US20240360120A1 (en) | 2024-10-31 |
| US20200291014A1 (en) | 2020-09-17 |
| KR20210127790A (ko) | 2021-10-22 |
| ZA202106284B (en) | 2023-02-22 |
| WO2020186006A1 (en) | 2020-09-17 |
| IL285889B1 (en) | 2024-05-01 |
| AU2020235089A1 (en) | 2021-09-23 |
| IL285889A (en) | 2021-10-31 |
| EP3938358A1 (en) | 2022-01-19 |
| US11247988B2 (en) | 2022-02-15 |
| CN114072390B (zh) | 2024-06-11 |
| PH12021552147A1 (en) | 2023-01-04 |
| JP7460649B2 (ja) | 2024-04-02 |
| US20220259198A1 (en) | 2022-08-18 |
| US11932636B2 (en) | 2024-03-19 |
| EP3938358B1 (en) | 2024-10-02 |
| SG11202109399SA (en) | 2021-09-29 |
| CN114072390A (zh) | 2022-02-18 |
| MX2021010916A (es) | 2021-10-01 |
| TW202104198A (zh) | 2021-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3938358B1 (en) | Rad51 inhibitors | |
| AU2018328818B2 (en) | RAD51 inhibitors | |
| JP7628090B2 (ja) | 膵臓がんの治療にｒａｄ５１阻害剤を利用する方法 | |
| HK40086120A (en) | Rad51 inhibitors | |
| HK40025149A (en) | Rad51 inhibitors | |
| HK40025149B (en) | Rad51 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220929 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240711 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240906 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241003 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250201 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250201 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260106 |